Abivax announced the repurchase of $90 million in royalty certificates, paying $45 million in cash and $45 million via a vendor loan set off by a $45 million American Depositary Shares (ADS) offering priced at $111.57 per ADS. This move reduces royalty obligations, simplifies the capital structure, and enhances financial flexibility. The company maintains a strong cash position with a runway into Q4 2027, supporting ongoing clinical programs and pre-commercial activities. The offering will dilute shares by approximately 0.5% and is expected to close around May 7, 2026.
ZenaTech's subsidiary ZenaDrone is beginning to schedule live demonstrations of its drone technology for U.S. government defense agencies, marking a key step from testing to market readiness. Initial demos will feature the IQ Nano indoor drone, with ...
Charles Schwab announced record second-quarter results with $7.07 billion in revenue and $1.62 adjusted EPS, a 42% increase year-over-year. The company added 1.4 million new brokerage accounts and $120 billion in net new assets, signaling strong clie...
D.R. Horton reported strong quarterly earnings with an EPS of $3.20 and revenue of $9.23 billion, both exceeding analyst expectations. The results were driven by a 4% increase in home-closing volumes, totaling nearly 24,000 homes, along with contribu...
The U.S. Small Business Administration (SBA) announced a $6 million grant competition to fund the Women’s Business Center (WBC) Modernization Initiative. This initiative aims to expand statewide support networks for women entrepreneurs in eight state...
Copart's stock is under pressure following a Barclays analyst downgrade to a $26 price target and significant insider selling by a company director. The company faces a securities fraud investigation after CEO Jeff Liaw's resignation, which caused an...
